Oregon § 743A.335 Human immunodeficiency virus

Oregon Statutes

§ 743A.335 — Human immunodeficiency virus

Oregon § 743A.335

Vol.18

Title 56Insurance

Ch. 743AHealth Insurance: Reimbursement of Claims

This text of Oregon § 743A.335 (Human immunodeficiency virus) is published on Counsel Stack Legal Research, covering Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Or. Rev. Stat. § 743A.335 (2026).

Text

(1)An insurer that offers a health benefit plan, as defined in ORS 743B.005, that reimburses the cost of counseling, prevention services or screening for sexually transmitted infections, shall provide coverage for:

(a)Drugs that have been approved by the United States Food and Drug Administration for the prevention of human immunodeficiency virus;

(b)Services necessary for the commencement or continuation of human immunodeficiency virus prevention drugs described in this section, including but not limited to office visits, testing, vaccinations and monitoring services; and

(c)Drugs that have been approved by the United States Food and Drug Administration for the treatment of human immunodeficiency virus.

(2)The coverage under subsection (1)(a) and (b) of this section must be provided

Free access — add to your briefcase to read the full text and ask questions with AI

(1) An insurer that offers a health benefit plan, as defined in ORS 743B.005, that reimburses the cost of counseling, prevention services or screening for sexually transmitted infections, shall provide coverage for:
(a) Drugs that have been approved by the United States Food and Drug Administration for the prevention of human immunodeficiency virus;
(b) Services necessary for the commencement or continuation of human immunodeficiency virus prevention drugs described in this section, including but not limited to office visits, testing, vaccinations and monitoring services; and
(c) Drugs that have been approved by the United States Food and Drug Administration for the treatment of human immunodeficiency virus.
(2) The coverage under subsection (1)(a) and (b) of this section must be provided without cost-sharing, coinsurance or deductibles applicable to the services.
(3) This section is exempt from ORS 743A.001.